E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Higher Risk Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
|
|
E.1.1.1 | Medical condition in easily understood language |
Higher Risk Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054350 |
E.1.2 | Term | Chronic myelomonocytic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028533 |
E.1.2 | Term | Myelodysplastic syndrome |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the relative effect of azacitidine plus birinapant versus azacitidine plus placebo on response rate [RR=complete response (CR) + partial response (PR)] using the modified International Working Group (IWG) Response Criteria for MDS, in patients with higher risk MDS, secondary MDS or CMMoL. |
|
E.2.2 | Secondary objectives of the trial |
To compare the effect of azacitidine plus birinapant relative to azacitidine plus placebo, on the
following:
• hematologic improvement (HI)
• relapse-free survival according to modified IWG 2006 criteria
• time to response
• change in transfusion requirements
• duration of response according to modified IWG 2006 criteria
• overall survival
• adverse event (AE) profile according to NCI CTCAE v.4.03 criteria |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. The subject is an adult greater than or equal to 18 years of age.
2. The subject is able to understand and voluntarily sign a written informed consent, and is willing and able to comply with the protocol requirements.
3. The subject has morphologically confirmed diagnosis of MDS or CMMoL according to FAB or WHO
classification, including RAEB-t and MDS/MPN classifications
4. International prognostic score-revised (IPSS-R) of >=3.5 (Intermediate, High or Very High).
5. Procedures to obtain specimens for establishing baseline disease must be done within 30 days prior to enrollment/randomization.
6. The subject was previously untreated with hypomethylating agents for MDS or CMMoL.
7. The subject has performance status of 0, 1 or 2 by the ECOG scale.
8. The subject has adequate liver function (bilirubin <= 1.2 x ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the upper limit of normal (ULN) or < 5 x ULN if related to leukemia tissue infiltration).
9. The subject has adequate renal function as evidenced by creatinine <= 2mg/dL (176.8 µmol/L).
10. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and negative (serum or urine) pregnancy test within 96 hours prior to the first study dose.
11. Female subjects of childbearing potential and male subjects with partners of childbearing potential should ensure use of a highly effective method of birth control as defined by the investigator, for example, those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectable, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner during the study and for a period of 3 months following the last dose of any drug administered during the study.
French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. |
|
E.4 | Principal exclusion criteria |
1. The subject has relapsed or is refractory to hypomethlating agents.
2. The subject has acute myeloid leukemia (AML) (except those patients with RAEB-t who are not candidates for intensive AML therapy).
3. The subject has been treated with an investigational agent within 4 weeks of randomization or 5 half lives (whichever is longer).
4. The subject received any hematopoietic growth factors within 14 days prior to screening.
5. The subject had prior malignancy or secondary malignancy within the prior 2 years (except in situ cervical cancer, squamous cell carcinoma or basal cell carcinoma of the skin).
6. The subject has known diagnosis of human immunodeficiency virus or chronic active Hepatitis B or C. Viral testing is not required.
7. The subject has uncontrolled hypertension (i.e., blood pressure >160/100 mmHg without medication, or not controlled despite medications).
8. The subject has impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or clinically significant cardiac disease including the following:
a. New York Heart Association grade III or IV congestive heart failure
b. documented myocardial infarction within the last 12 months
9. The subject has not recovered from prior adverse events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) (except alopecia) due to therapy
administered prior to the initiation of study drug dosing.
10. The subject is nursing or pregnant.
11. The subject has known allergy or hypersensitivity to any of the formulation components of birinapant, placebo or azacitidine, including mannitol, citric acid monohydrate, sodium citrate dehydrate, and sodium
chloride.
12. The subject has a history of cranial nerve palsy.
13. The subject has any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation, render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen), or limit the subject's compliance with the protocol's required evaluations.
14. The subject is being treated with anti-TNF therapies or has been treated with an anti-TNF therapy within 5
half-lives of randomization. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable is response rate. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The final determination of response will be based on the evaluations by the independent reviewer(s) blinded to treatment assignment and will be used for the study’s efficacy analysis |
|
E.5.2 | Secondary end point(s) |
Efficacy:
•Hematologic improvement (HI)
• Relapse free survival (RFS)
• Time to response (TTR)
• Change in Transfusion requirements:
• Duration of response (DR)
• Overall survival(OS)
Safety:
Safety assessments include adverse events, clinical laboratory testing, vital signs measurements, physical examination findings, ECOG performance status, and concomitant medication usage |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
HI assessed per Cheson et al 2006 hematological criteria
RFS: from randomization to first relapse or death
TTR: from randomization to first response
Transfusion from 8 wk prior to randomization, monthly
DR: from initial response to first relapse or death
OS: from randomization to death
AEs: throughout to 30d after last dose
Hematology: at screening, d1 and 15 of each cyc, wk4 of every 4th cyc, follow-up
Serum chemistry: at screening, d1 and 15 of each cyc, follow-up
Urinalysis: at screening
Bone Marrow: at screening, wk4 of every 4th cyc
Serum Pregnancy: at screening
Vital signs: at screening, prior to each drug administration and after study drug administration, follow up
Concomitant therapy: Throughout study
ECOG: at screening, day 1 of each cy, follow-up
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Germany |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |